Maxim Ceplene Expanded Access Program To Enroll Up To 1,000 Melanoma Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
The Treatment IND program is directed at Stage IV malignant melanoma patients. Maxim predicts amending its 2000 NDA for histamine dihydrochloride with the confirmatory Phase III results in early 2005.